Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHF8 | Q9UPP1 | 7/20 | 0.54 |
| ▸ | KDM2A | Q9Y2K7 | 7/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | KDM5C | P41229 | 4/20 | 0.54 |
| ▸ | KDM6B | O15054 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3908353 | 0.97 | PHF8 (0.52) | PHF8KDM2AEGLN1KDM4EKDM5C | |
| Succinic Acid SCHEMBL3862565 | 0.83 | EGLN1 (0.53) | PHF8KDM2AEGLN1KDM4EKDM5C | |
| Succinic Acid SCHEMBL3710655 | 0.83 | EGLN1 (0.53) | PHF8KDM2AEGLN1KDM4EKDM5C | |
| SCHEMBL1641076 | 0.79 | ALDH1A1 (0.53) | PHF8KDM2AEGLN1KDM4EKDM5C | |
| SCHEMBL3711246 | 0.78 | — | — | |
| SCHEMBL30934742 | 0.77 | PHF8 (0.52) | PHF8KDM2AEGLN1KDM4EKDM5C | |
| Succinic Acid SCHEMBL5875205 | 0.76 | EGLN1 (0.69) | PHF8KDM2AEGLN1KDM4EKDM5C | |
| Succinic Acid SCHEMBL5875196 | 0.76 | EGLN1 (0.69) | PHF8KDM2AEGLN1KDM4EKDM5C | |
| SCHEMBL28566925 | 0.76 | — | — | |
| SCHEMBL3641706 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576077-B2 | Composition for preventing, alleviating or treating cancer | CKP THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4523674-B1 | COMPOSITION FOR PROMOTING PHOTOPROTECTION AND CUTANEOUS REGENERATION THROUGH SEQUENTIAL PHOTONIC TRANSFER (SPT) | ESPADA REGALADO JESUS (ES) | 2025-10-15 | — | — | EP | claimed |
| US-20250288509-A1 | Composition for Promoting Photoprotection and Cutaneous Regeneration through Sequential Photonic Transfer (SPT) | REGALADO, JESUS ESPADA (ES) | 2025-09-18 | — | — | US | claimed |
| EP-4602049-A1 | SOS1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-08-20 | — | — | EP | claimed |
| EP-4587439-A1 | SULFONE-SUBSTITUTED PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-07-23 | — | — | EP | claimed |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-05-15 | — | — | US | claimed |
| US-20250145573-A1 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER | CKP THERAPEUTICS, INC. | 2025-05-08 | — | — | US | claimed |
| EP-4523674-A1 | COMPOSITION FOR PROMOTING PHOTOPROTECTION AND CUTANEOUS REGENERATION THROUGH SEQUENTIAL PHOTONIC TRANSFER (SPT) | ESPADA REGALADO, Jesús (ES) | 2025-03-19 | — | — | EP | claimed |
| CN-114630830-B | Novel compounds, pharmaceutical compositions comprising the same and uses thereof | 治愈医药社株式会社 | 2025-02-25 | — | — | CN | claimed |
| WO-2025021997-A1 | NEW MAP4K1 INHIBITORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-01-30 | — | — | WO | claimed |
| US-20170042938-A1 | MODIFICATION OF EXTRACORPOREAL PHOTOPHERISIS TECHNOLOGY WITH PORPHYRIN PRECURSORS | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2017-02-16 | — | — | US | claimed |
| US-20160367674-A1 | COMBINATION ARTEMISININ AND CHEMILUMINESCENT PHOTODYNAMIC THERAPY AND USES THEREFOR | WASHINGTON UNIVERSITY | 2016-12-22 | — | — | US | claimed |
| WO-2016174183-A1 | COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | WO | claimed |
| WO-2015162279-A1 | MODIFICATION OF EXTRACORPOREAL PHOTOPHERESIS TECHNOLOGY WITH PORPHYRIN PRECURSORS | OSLO UNIVERSITETSSYKEHUS HF (NO) | 2015-10-29 | — | — | WO | claimed |
| US-9056133-B2 | Pharmaceutical kit and method for treating cancer | CTI-S.A. (CL) | 2015-06-16 | — | — | US | claimed |
| US-20140235559-A1 | ANTI-CANCER PHARMACEUTICAL COMPOSITION | HANALL BIOPHARMA CO., LTD. (KR) | 2014-08-21 | — | — | US | claimed |
| US-20140235558-A1 | PHARMACEUTICAL COMPOSITION HAVING ACTIVITY OF ANTICANCER | HANALL BIOPHARMA CO., LTD. (KR) | 2014-08-21 | — | — | US | claimed |
| US-20130084263-A1 | Pharmaceutical kit and method for treating cancer | PODHAJCER OSVALDO (AR) | 2013-04-04 | — | — | US | claimed |
| EP-2054051-B1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | AMDERMA PHARMACEUTICALS LLC (US) | 2013-02-27 | — | — | EP | claimed |
| WO-2013019058-A2 | PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER RECURRENCE OR METASTASIS | HANALL BIOPHARMA CO., LTD. (KR) | 2013-02-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576077-B2 | Composition for preventing, alleviating or treating cancer | ERBB2, EGFR, BRAF | PHF8 3722/4885KDM2A 4071/4885EGLN1 2764/4885 |
| US-20250154170-A1 | FUSED PYRIMIDINES AS KRAS INHIBITORS | KRAS, NRAS, TP53 | PHF8 2481/4885KDM2A 3046/4885EGLN1 1727/4885 |
| US-20140235559-A1 | ANTI-CANCER PHARMACEUTICAL COMPOSITION | SLC5A2, SLC5A1, SLC2A1 | PHF8 757/4885KDM2A 1199/4885EGLN1 558/4885 |
| US-20140235558-A1 | PHARMACEUTICAL COMPOSITION HAVING ACTIVITY OF ANTICANCER | SLC2A1, SLC2A3, SLC5A2 | PHF8 746/4885KDM2A 1003/4885EGLN1 717/4885 |
| US-20250145573-A1 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER | ABCC1, BRCA1, TP53 | PHF8 2858/4885KDM2A 4030/4885EGLN1 1755/4885 |
| US-20170042938-A1 | MODIFICATION OF EXTRACORPOREAL PHOTOPHERISIS TECHNOLOGY WITH PORPHYRIN PRECURSORS | ENPEP, PPOX, PRCP | PHF8 568/4885KDM2A 1707/4885EGLN1 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.